Is Sunlenca a Long-Acting HIV Treatment?
Sunlenca (lenacapavir) is an FDA-approved HIV-1 capsid inhibitor for multidrug-resistant HIV in heavily treatment-experienced adults. It is administered subcutaneously every 6 months, making it one of the longest-acting HIV treatments available, with dosing as infrequent as twice yearly after an initial oral lead-in.[1][2]
How Is Sunlenca Dosed?
Treatment starts with oral lenacapavir capsules (300 mg twice daily) for 2 days, followed by a 2 mL subcutaneous injection (463.5 mg). Maintenance injections occur every 6 months. This regimen reduces pill burden compared to daily oral antiretrovirals.[1][3]
How Does Sunlenca Compare to Other Long-Acting HIV Options?
Unlike daily pills like Biktarvy, Sunlenca offers 6-month protection. Cabenuva (cabotegravir + rilpivirine), another long-acting injectable, requires shots every 1-2 months. Sunlenca targets the HIV capsid protein for broad activity against resistant strains, often used with other drugs like ritonavir-boosted darunavir.[1][4]
| Treatment | Dosing Frequency | Target Population |
|-----------|------------------|-------------------|
| Sunlenca | Every 6 months (subQ) | Multidrug-resistant HIV |
| Cabenuva | Every 1-2 months (IM) | Virologically suppressed adults |
| Apretude (cabotegravir PrEP) | Every 2 months (IM) | HIV prevention |
Who Qualifies for Sunlenca?
Approved for adults with HIV-1 resistant to at least one drug from three classes (NRTIs, NNRTIs, PIs), despite optimized therapy. Not for initial treatment or PrEP. Clinical trials (CAPELLA) showed 83% achieved viral suppression at week 52.[1][2]
What Side Effects Do Patients Report?
Common issues include injection-site reactions (63%, mostly mild swelling/nodules resolving in weeks), nausea (13%), and diarrhea (9%). Long-term data show reactions decrease over time; no HIV resistance emerged in trials.[1][3]
When Did Sunlenca Get Approved and What's Next?
FDA approved December 2022. Ongoing trials explore twice-yearly use for treatment-naive patients and PrEP (83% efficacy in CALIBRATE study). No pediatric approval yet.[2][5]
Cost and Access Details
List price is about $42,250 per 6-month injection (2023 data), or $84,500 yearly. Patient assistance programs cover most insured patients; check manufacturer savings cards.[6]
Sources
[1]: Sunlenca Prescribing Information (Gilead)
[2]: FDA Approval Summary
[3]: CAPELLA Trial (NEJM)
[4]: Cabenuva Prescribing Information (ViiV)
[5]: Gilead Pipeline Updates
[6]: GoodRx Pricing Data